Best GLP-1 Telehealth Providers (2026)

Time-to-prescription, end-to-end

This is the metric most consumer reviews skip. We measure it from the moment intake starts to the moment a prescription lands at a pharmacy or partner. Cash-pay compounded programs should be 24–72 hours; insured brand-name pursuit (Wegovy, Zepbound) with prior authorization should be 3–10 business days. Anything beyond two weeks suggests the program doesn't have a real PA team and is functionally a consumer relay between you and your insurance — at which point you'd be better off going through your primary-care clinician.

Clinician credentials, verifiable

Look for prescribing clinicians who are board-certified MDs, DOs, or NPs licensed in your state. Better programs name the clinical leadership and disclose state board numbers on request. Programs that obscure who is prescribing — “our medical team,” “our network of providers,” nothing more specific — are almost always either contracting through aggregator platforms or relying on cross-state telemedicine compacts in ways the state board would investigate.

Pricing transparency on first checkout

The number you see on the homepage should be the number you see at checkout. Hidden fees, surprise lab charges, post-trial price escalation, and auto-renewal traps are the most common consumer complaints in the GLP-1 telehealth category. The FTC issued enforcement guidance in 2025 for negative-option marketing in this space; programs that comply will show post-trial pricing on the first checkout screen, not buried in terms of service.

Prior-authorization capability for insured patients

If you have commercial insurance and you want brand-name Ozempic, Wegovy, or Zepbound, the bottleneck isn't cost — it's the prior auth your plan requires before it'll cover the drug. Programs with dedicated PA teams (specifically Ro, Found, WeightWatchers Clinic, LifeMD) close approvals in days. Programs without PA capability will either send you a denial after the first week or push you toward their cash-pay compounded option, regardless of what you signed up for.

Ongoing clinical support

GLP-1 therapy is a 12-month-plus engagement, not a one-shot prescription. Side-effect management, dose-titration timing, and weight-plateau strategy all matter to outcome. Better programs include unlimited clinician messaging, scheduled check-ins at week 4 / 12 / 24, and a clear protocol for how to handle missed doses, travel, and vomiting episodes. Programs that hand you a prescription and disappear are charging membership fees for a service they're not delivering.

The single biggest decision in this category is the cash-pay vs. insured fork. Cash-pay compounded programs are faster, simpler, and cheaper out-of-pocket on month one — but the molecule is compounded semaglutide or compounded tirzepatide, not Ozempic or Mounjaro. Insured brand-name programs are more expensive in raw dollars and slower to start, but the drug is FDA-reviewed at the specific dose, the manufacturer savings card can drop the patient cost to $0–$25, and the insurance company is on the hook for ongoing coverage.

Our default recommendation: if you have commercial insurance and your plan covers Wegovy or Zepbound, go with a brand-name program with a strong PA team. If you're cash-pay, federal-plan-only, or your insurer has refused coverage twice, go with a compounded program from a state-licensed pharmacy. The patient outcomes on both paths, in our reader-panel data, are clinically similar at 12 months.